Phosphorylated α-synuclein can be detected in blood plasma and is potentially a useful biomarker for Parkinson's disease

被引：166
作者：
Foulds, Penelope G. [1 ]
Mitchell, J. Douglas [3 ]
Parker, Angela [3 ]
Turner, Roisin [3 ]
Green, Gerwyn [2 ]
Diggle, Peter [2 ]
Hasegawa, Masato [4 ]
Taylor, Mark [1 ]
Mann, David [5 ]
Allsop, David [1 ]
机构：
[1] Univ Lancaster, Sch Hlth & Med, Div Biomed & Life Sci, Lancaster LA1 4AY, England
[2] Univ Lancaster, Sch Hlth & Med, Div Hlth Res, Lancaster LA1 4AY, England
[3] Royal Preston Hosp, Preston, Lancs, England
[4] Tokyo Inst Psychiat, Dept Mol Neurobiol, Tokyo, Japan
[5] Univ Manchester, Hope Hosp, Sch Community Based Med, Neurodegenerat & Mental Hlth Res Grp, Salford M6 8HD, Lancs, England
来源：
FASEB JOURNAL | 2011年 / 25卷 / 12期
基金：
英国医学研究理事会;
关键词：
Lewy body; oligomer; immunoassay; immunoblot; LEWY BODY; NEURODEGENERATIVE DISORDERS; CLINICAL-DIAGNOSIS; DEMENTIA; SER-129; BODIES; OLIGOMERS; MUTATION; MODEL; CSF;
D O I：
10.1096/fj.10-179192
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
Parkinson's disease (PD) is characterized by the presence of Lewy bodies containing phosphorylated and aggregated alpha-synuclein (alpha-syn). alpha-Syn is present in human body fluids, including blood plasma, and is a potential biomarker for PD. Immunoassays for total and oligomeric forms of both normal and phosphorylated (at Ser-129) alpha-syn have been used to assay plasma samples from a longitudinal cohort of 32 patients with PD (sampled at mo 0, 1, 2, 3), as well as single plasma samples from a group of 30 healthy control participants. The levels of alpha-syn in plasma varied greatly between individuals, but were remarkably consistent over time within the same individual with PD. The mean level of phospho-alpha-syn was found to be higher (P=0.053) in the PD samples than the controls, whereas this was not the case for total alpha-syn (P=0.244), oligo-alpha-syn (P=0.221), or oligo-phospho-alpha-syn (P=0.181). Immunoblots of plasma revealed bands (at 21, 24, and 50-60 kDa) corresponding to phosphorylated alpha-syn. Thus, phosphorylated alpha-syn can be detected in blood plasma and shows more promise as a diagnostic marker than the nonphosphorylated protein. Longitudinal studies undertaken over a more extended time period will be required to determine whether alpha-syn can act as a marker of disease progression.-Foulds, P. G., Mitchell, J. D., Parker, A., Turner, R., Green, G., Diggle, P., Hasegawa, M., Taylor, M., Mann, D., Allsop, D. Phosphorylated alpha-synuclein can be detected in blood plasma and is potentially a useful biomarker for Parkinson's disease. FASEB J. 25, 4127-4137 (2011). www.fasebj.org
引用
收藏
页码：4127 / 4137
页数：11
相关论文
共 54 条
[1]   Phosphorylation of Ser-129 is the dominant pathological modification of α-synuclein in familial and sporadic Lewy body disease [J].
Anderson, John P. ;
Walker, Donald E. ;
Goldstein, Jason M. ;
de laat, Rian ;
Banducci, Kelly ;
Caccavello, Russell J. ;
Barbour, Robin ;
Huang, Jiping ;
Kling, Kristin ;
Lee, Michael ;
Diep, Linnea ;
Keim, Pamela S. ;
Shen, Xiaofeng ;
Chataway, Tim ;
Schlossmacher, Michael G. ;
Seubert, Peter ;
Schenk, Dale ;
Sinha, Sukanto ;
Gai, Wei Ping ;
Chilcote, Tamie J. .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2006, 281 (40) :29739-29752
[2]   Dissecting the potential molecular mechanisms underlying a-synuclein cell-to-cell transfer in Parkinson's disease [J].
Angot, Elodie ;
Brundin, Patrik .
PARKINSONISM & RELATED DISORDERS, 2009, 15 :S143-S147
[3]   Red blood cells are the major source of alpha-synuclein in blood [J].
Barbour, Robin ;
Kling, Kristin ;
Anderson, John P. ;
Banducci, Kelly ;
Cole, Tracy ;
Diep, Linnea ;
Fox, Michael ;
Goldstein, Jason M. ;
Soriano, Ferdie ;
Seubert, Peter ;
Chilcote, Tarnie J. .
NEURODEGENERATIVE DISEASES, 2008, 5 (02) :55-59
[4]   Imaging Approaches to Parkinson Disease [J].
Brooks, David J. .
JOURNAL OF NUCLEAR MEDICINE, 2010, 51 (04) :596-609
[5]   α-synuclein locus duplication as a cause of familial Parkinson's disease [J].
Chartier-Harlin, MC ;
Kachergus, J ;
Roumier, C ;
Mouroux, V ;
Douay, X ;
Lincoln, S ;
Levecque, C ;
Larvor, L ;
Andrieux, J ;
Hulihan, M ;
Waucquier, N ;
Defebvre, L ;
Amouyel, P ;
Farrer, M ;
Destée, A .
LANCET, 2004, 364 (9440) :1167-1169
[6]   Subjective complaints, precede Parkinson disease - The Rotterdam study [J].
de Lau, LML ;
Koudstaal, PJ ;
Hofman, A ;
Breteler, MMB .
ARCHIVES OF NEUROLOGY, 2006, 63 (03) :362-365
[7]   Plasma α-Synuclein in Patients with Parkinson's Disease With and Without Treatment [J].
Duran, Raquel ;
Barrero, Francisco J. ;
Morales, Blas ;
Luna, Juan D. ;
Ramirez, Manuel ;
Vives, Francisco .
MOVEMENT DISORDERS, 2010, 25 (04) :489-493
[8]   A strategy for designing inhibitors of α-synuclein aggregation and toxicity as a novel treatment for Parkinson's disease and related disorders [J].
El-Agnaf, OMA ;
Paleologou, KE ;
Greer, B ;
Abogrein, AM ;
King, JE ;
Salem, SA ;
Fullwood, NJ ;
Benson, FE ;
Hewitt, R ;
Ford, KJ ;
Martin, FL ;
Harriot, P ;
Cookson, MR ;
Allsop, D .
FASEB JOURNAL, 2004, 18 (09) :1315-+
[9]   α-synuclein implicated in Parkinson's disease is present in extracellular biological fluids, including human plasma [J].
El-Agnaf, OMA ;
Salem, SA ;
Paleologou, KE ;
Cooper, LJ ;
Fullwood, NJ ;
Gibson, MJ ;
Curran, MD ;
Court, JA ;
Mann, DMA ;
Ikeda, S ;
Cookson, MR ;
Hardy, J ;
Allsop, D .
FASEB JOURNAL, 2003, 17 (11) :1945-+
[10]   Soluble oligomers for the diagnosis of neurodegenerative diseases [J].
El-Agnaf, OMA ;
Walsh, DM ;
Allsop, D .
LANCET NEUROLOGY, 2003, 2 (08) :461-462
123456